Skip to main content
/ Erasmus MC

Studies van Erasmus MC (Longkanker Netwerk Zuid-West Nederland)

In het studieoverzicht zijn de studies gerubriceerd naar de volgende stadia: vroeg-, lokaal gevorderd- en gevorderd stadium. Daarnaast ie gekozen voor een indeling in niet kleincellig longkanker, kleincellig longkanker en overige thoracale tumoren/studies.

Vragen over een studie?

Contact opnemen

NSCLC

GENMAB

2e lijn

A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor

Hydrapem

1e lijn 

The effect of extra hydration on kidney function during carboplatinpemetrexed-pembrolizumab in patients with advanced non-small cell lung cancer

TEIPP

2e lijn 

T-cell Epitopes associated with Impaired Peptide Processing (TEIPP)-targeting immunotherapy in patients with relapsed advanced non small cell lung cancer (NSCLC)

TROPION LUNG01

2e lijn

Phase3 randomized study of DS-1062A versus docetaxel in previously treated advanced or metastatic Non Small Cell Lung cancer with actionable genomic alterations

DEDICATION-1

Lijn ongevoelig


Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLC

EVOKE

Lijn ongevoelig

Open-Label, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Checkpoint Inhibitors

ImmunoSABR

Phase II trial testing if the combination of stereotactic ablative body radiotherapy (SABR) and L19-IL2 improve the progression-free survival in patients with limited metastatic non-small cell lung cancer (NSCLC). The trial consists of one cohort with two arms; C-arm and an E-arm

DEDICATION-1

Lijn ongevoelig
Mutatie ongevoelig

Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLC

EVOKE

Lijn ongevoelig
Mutatie ongevoelig

Open-Label, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Checkpoint Inhibitors

ImmunoSABR

1e lijn
Mutatie ongevoelig

A clinical imaging study using [18F]F-AraG PET to visualize Tumor infiltrating T-cell Activation in Non-small cell lung cancer

Entrectinib

1e lijn 
ROS-1

Randomized, Open Label, Multicenter, Phase III Study Of Entrectinib Versus Crizotinib In Patiemts With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer harboring ROS-1 Gene Rearrangements With And Without Central Nervous System Metastases

KRYSTAL

1e lijn 
KRAS G12C

Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

MARIPOSA

1e lijn na chemo-immuno
EGFR

Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

ORCHARD

2e lijn na osimertinib
EGFR

Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progressed on First-Line Osimertinib Therapy

SCLC

MK-7684A

1e lijn

Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer

Mesothelioom

Ensure

Phase I, Open-Label Study With Dendritic Cell therapy (MesoPher) In Combination With Extended- Pleurectomy/Decortication After Chemotherapy in Subjects With Resectable Mesothelioma

MESOPEC

Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma

Contact opnemen over een studie

Voor meer informatie over de studies van de afdeling long oncologie van Erasmus MC kan met onderstaande contactpersonen contact worden opgenomen.

Secretariaat
long.oncologie@erasmusmc.nl